SLC2A1 and cancer: Various studies showed that sorafenib could stabilize HIF-1α expression under hypoxia and increase the expression of HIF-1α targets like MDR1, GLUT-1, VEGF and miRNAs (e.g. miR-210), and the whole progress played vital roles in cancer biology [34–36].